University of Iowa Hospitals and Clinics
Participants in this study are diagnosed with renal cell cancer (RCC). The purpose of this study is to evaluate the effect of study drug cabozantinib compared with everolimus on overall survival (OS) and progression-free survival (PFS) in subjects with advanced RCC. This study will be take place at approximately 200 global clinical sites with a total of about 650 participants. Approximately 9 participants will take part in this study at the University of Iowa.
Julie Schlabaugh Julie-Schlabaugh@uiowa.edu
We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.